Nuveen’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$537M Sell
1,081,685
-2,810
-0.3% -$1.25M 0.13% 125
2026
Q1
$484M Buy
1,084,495
+42,098
+4% +$19.6M 0.13% 137
2025
Q4
$473M Sell
1,042,397
-35,313
-3% -$15.2M 0.12% 137
2025
Q3
$422M Buy
1,077,710
+15,475
+1% +$6.47M 0.11% 157
2025
Q2
$473M Buy
1,062,235
+63,817
+6% +$29.4M 0.13% 139
2025
Q1
$484M Sell
998,418
-52,693
-5% -$24.6M 0.15% 133
2024
Q4
$423M Buy
1,051,111
+261,891
+33% +$121M 0.12% 146
2024
Q3
$367M Sell
789,220
-15,130
-2% -$7.27M 0.1% 165
2024
Q2
$377M Sell
804,350
-31,367
-4% -$13.6M 0.11% 146
2024
Q1
$349M Sell
835,717
-5,406
-0.6% -$2.29M 0.1% 170
2023
Q4
$342M Buy
841,123
+28,536
+4% +$10.5M 0.11% 165
2023
Q3
$283M Sell
812,587
-39,405
-5% -$13.8M 0.1% 182
2023
Q2
$300M Sell
851,992
-56,336
-6% -$19M 0.1% 166
2023
Q1
$286M Sell
908,328
-1,703
-0.2% -$511K 0.11% 175
2022
Q4
$263M Sell
910,031
-424,810
-32% -$129M 0.1% 191
2022
Q3
$386M Buy
1,334,841
+82,937
+7% +$23.9M 0.16% 130
2022
Q2
$353M Sell
1,251,904
-5,830
-0.5% -$1.56M 0.14% 142
2022
Q1
$315M Sell
1,257,734
-86,100
-6% -$20.4M 0.1% 187
2021
Q4
$295M Sell
1,343,834
-21,391
-2% -$4.16M 0.09% 212
2021
Q3
$248M Sell
1,365,225
-1,441,437
-51% -$281M 0.08% 233
2021
Q2
$566M Buy
2,806,662
+63,271
+2% +$13.2M 0.17% 118
2021
Q1
$590M Buy
2,743,391
+121,953
+5% +$26.8M 0.19% 110
2020
Q4
$620M Sell
2,621,438
-880,517
-25% -$202M 0.21% 98
2020
Q3
$953M Buy
3,501,955
+23,572
+0.7% +$6.5M 0.37% 58
2020
Q2
$1.01B Buy
3,478,383
+726,720
+26% +$197M 0.41% 49
2020
Q1
$655M Buy
2,751,663
+238,591
+9% +$54.7M 0.32% 69
2019
Q4
$550M Buy
2,513,072
+445,821
+22% +$90.2M 0.21% 103
2019
Q3
$350M Sell
2,067,251
-240,152
-10% -$42.5M 0.14% 144
2019
Q2
$423M Buy
2,307,403
+2,292,058
+14,937% +$401M 0.17% 123
2019
Q1
$2.82M Sell
15,345
-3
-0% -$554 0.02% 596
2018
Q4
$2.54M Sell
15,348
-108
-0.7% -$18.7K 0.02% 588
2018
Q3
$2.98M Sell
15,456
-490
-3% -$87.3K 0.02% 601
2018
Q2
$2.71M Sell
15,946
-2,375
-13% -$368K 0.02% 579
2018
Q1
$2.99M Sell
18,321
-9,076
-33% -$1.48M 0.02% 542
2017
Q4
$4.11M Sell
27,397
-61,138
-69% -$9.05M 0.03% 487
2017
Q3
$13.5M Sell
88,535
-31,684
-26% -$4.77M 0.09% 328
2017
Q2
$15.5M Buy
120,219
+53,439
+80% +$6.43M 0.1% 307
2017
Q1
$7.3M Buy
66,780
+10,093
+18% +$889K 0.04% 473
2016
Q4
$4.18M Sell
56,687
-125,609
-69% -$10.2M 0.02% 669
2016
Q3
$15.9M Buy
182,296
+24,658
+16% +$2.33M 0.09% 258
2016
Q2
$13.6M Buy
157,638
+141,721
+890% +$12.2M 0.08% 291
2016
Q1
$1.27K Sell
15,917
-249
-2% -$22.5K 0.01% 935
2015
Q4
$2.03K Sell
16,166
-892
-5% -$108K 0.01% 766
2015
Q3
$1.78K Buy
17,058
+636
+4% +$81.7K 0.01% 807
2015
Q2
$2.03K Sell
16,422
-29,355
-64% -$3.7M 0.01% 815
2015
Q1
$5.4M Sell
45,777
-65,937
-59% -$7.9M 0.03% 511
2014
Q4
$13.3M Sell
111,714
-127,854
-53% -$14.4M 0.07% 335
2014
Q3
$26.9M Buy
239,568
+41,928
+21% +$3.99M 0.17% 158
2014
Q2
$18.7M Buy
197,640
+160,450
+431% +$11.3M 0.11% 248
2014
Q1
$2.63M Sell
37,190
-548
-1% -$43.4K 0.02% 704
2013
Q4
$2.8M Sell
37,738
-14
-0% -$975 0.02% 653
2013
Q3
$2.86M Sell
37,752
-64,097
-63% -$5.1M 0.02% 667
2013
Q2
$8.15M Buy
+101,849
New +$7.5M 0.05% 396

Other funds holding VRTX

Nuveen's VRTX Position: Q2 2026 in Review

Nuveen reduced its Vertex Pharmaceuticals (VRTX) stake by 0.26% in Q2 2026, selling an estimated $1.25M and leaving 1,081,685 shares worth $537M. The position accounts for 0.13% of the portfolio, ranked #125.

Nuveen first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.01B in Q2 2020. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Nuveen held 1,081,685 shares of Vertex Pharmaceuticals worth $537M as of Q2 2026.
  • Nuveen sold 2,810 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.25M.
  • Vertex Pharmaceuticals made up 0.13% of Nuveen's portfolio in Q2 2026, its #125 holding.
  • Nuveen first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Nuveen's Vertex Pharmaceuticals position peaked at $1.01B in Q2 2020.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.